COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01084369
Recruitment Status : Terminated (Withdrawal of sponsorship)
First Posted : March 10, 2010
Last Update Posted : April 4, 2019
Information provided by (Responsible Party):
Dr Edward Jude, Tameside Hospital NHS Foundation Trust

Brief Summary:
Diabetes mellitus is associated with long-term complications affecting mainly the eyes, nerves and kidneys. One of the main underlying causes for this is damage to the lining of the small blood vessels supplying these organs with dysfunction of the endothelium (lining of the small blood vessels). Testosterone has been shown to have an effect macro (large) blood vessels with limited data available on the micro (small) blood vessels. Testosterone is recognised to have important effects on metabolism and vascular behaviour beyond the accepted effects on secondary sexual characteristics. Physiological testosterone therapy is associated with some beneficial effects on the cardiovascular system and has been used with some success to treat patients with stable angina and chronic heart failure. The investigators therefore propose to study the effects of testosterone replacement therapy in patients with hypogonadism (low testosterone levels) on the endothelium in males with type 2 diabetes. 40 diabetic patients with type 2 diabetes and low testosterone levels and erectile dysfunction (impotence) will be recruited into the study. All patients will receive testosterone replacement therapy and 10 patients will also receive Vardenafil (a drug used to treat impotence). The investigators hope to demonstrate an improvement in endothelial dysfunction by assessing biochemical markers such as nitric oxide (a chemical that causes relaxation for the blood vessels) and C-reactive protein (a chemical that can increase in patients with diabetes) as well as the effect on weight, blood pressure, diabetes control and cholesterol.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Hypogonadism Drug: Testosterone Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IV: Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism
Actual Study Start Date : October 11, 2013
Actual Primary Completion Date : September 14, 2014
Actual Study Completion Date : September 14, 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Testosterone, Vardenafil
All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
Drug: Testosterone

NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.

Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.

Other Names:
  • Testosterone (NEBIDO)
  • Vardenafil (Levitra)

Primary Outcome Measures :
  1. Improvement in endothelial dependent and endothelial-independent vasodilatation [ Time Frame: 30 and 54 weeks ]
    Improvement in markers of endothelial function

Secondary Outcome Measures :
  1. Markers of endothelial function [ Time Frame: 54 weeks ]

    Secondary efficacy variables will include changes of the following

    • Availability of nitric oxide
    • Endothelial inflammation as measured by CRP
    • Serum levels of endothelial markers: IGF and adhesion molecules
    • BMI, waist circumference, glycaemic control (HbA1c), lipid profile and blood pressure.
    • Other laboratory parameters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 40 male patients with type 2 diabetes mellitus.
  • T2DM as judged by WHO criteria:

    • onset of diabetes mellitus after the age of 30 years
    • blood glucose controlled by diet or drugs other than insulin, or insulin initiated after 2 years diagnosis of diabetes
    • no history of diabetic ketoacidosis.
  • Symptomatic Hypogonadism as defined by:

    • Total testosterone below 10 nmol/l
    • Aging males' symptom score (AMS) above 36.
  • Hypogonadic men with erectile dysfunction
  • Age range- 50-80 years

Exclusion Criteria:

  • Patients with uncontrolled hypertension (BP>145/95 on treatment) or significant hypotension. (BP<100 systolic)
  • Current smokers
  • Recent myocardial infarction (<6 months), unstable angina or ongoing chest pain, recent (within 6 months) cardiac intervention (e.g. angioplasty, stenting or CABG) or stroke.
  • Patients with clinical nephropathy (24 hr protein >0.5 g or urine protein +) or moderate renal failure (serum creatinine >150 micromol/l).
  • History of prostate cancer or suspicion of prostate cancer on clinical examination
  • Androgen dependent carcinoma of the male mammary gland
  • Liver tumours
  • Hypersensitivity to NEBIDO or LEVITRA
  • Polycythaemia
  • General systemic illness, including cardiac, renal or hepatic insufficiency
  • Patients on nitrates will not be included in the Levitra arm.
  • History of loss of vision in one eye because of non arteritic ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
  • Hereditary degenerative retinal disorders such as retinitis pigmentosa.
  • Clinically significant chronic haematological disease which may lead to priapism
  • Bleeding disorders
  • Significant active peptic ulceration.
  • Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is contraindicated, as they are potent inhibitors of CYP 3A4
  • Concomitant use of vardenafil with potent CYP 3A4 inhibitors ketoconazole and itraconazole (oral form) is contra-indicated in men older than 75 years.
  • Patients deemed unable to comply with the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01084369

Layout table for location information
United Kingdom
Tameside General Hospital
Ashton-under-Lyne, Lancashire, United Kingdom, OL6 9RW
Tameside Hospital NHS Foundatoin Trust
Ashton under Lyne, United Kingdom, OL69RW
Sponsors and Collaborators
Tameside Hospital NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Edward Jude, MD, MRCP Tameside Hospital NHS Foundation Trust
Layout table for additonal information
Responsible Party: Dr Edward Jude, Consultant Physician, Tameside Hospital NHS Foundation Trust Identifier: NCT01084369    
Other Study ID Numbers: Testosterone version1
First Posted: March 10, 2010    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019
Keywords provided by Dr Edward Jude, Tameside Hospital NHS Foundation Trust:
Type 2 diabetes
Endothelial dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Gonadal Disorders
Vardenafil Dihydrochloride
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents